Related Experiment Video
Updated: May 5, 2026
Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
Published on: March 6, 2012
Hypofractionated radiotherapy for glioblastoma: correlation with prognostic factors and survival outcomes
Dimcho Georgiev1, Svetlana Bilyukova1, Cyril Kounin2
1University Specialized Hospital for Active Treatment of Oncology "Prof. Ivan Tzernozemski", Sofia, Bulgaria.
Background:
The purpose was to evaluate the efficacy of hypofractionated radiotherapy (HFRT) followed by conventional fractionated radiotherapy (CFRT) in glioblastoma multiforme (GBM) patients and identify prognostic factors.
Materials And Methods:
We conducted a retrospective analysis of 120 GBM patients treated postoperatively between 2010 and 2017 with HFRT (30 Gy in 3 Gy fractions) followed by CFRT (24 Gy in 2 Gy fractions), for a total dose of 60 Gy. All patients received concurrent and adjuvant temozolomide (TMZ).
Results:
Median age was 62.5 years. Median overall survival (OS) was 11.3 months; 1-, 2-, and 3-year survival rates were 43.3%, 16.1%, and 4.6%, respectively. Full dose completion correlated with improved OS (12.2 vs. 7.3 vs. 4.6 months for ≥ 100%, 90-99%, and < 70% dose realization, respectively). Age ≤ 63 years and gros tumor volume (GTV) ≤ 44.5 cm3 were associated with significantly better survival. Gender had no significant impact.
Conclusions:
HFRT followed by CFRT with TMZ is an effective alternative to standard CFRT in patients with subtotal or partial resection. Age and tumor volume are independent prognostic factors for overall survival.
